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function by echocardiography. After exclusion of pa-
tients in whom Angiotensin Converting Enzyme (ACE)
inhibitors were contraindicated, only seventy-five (58%)
patients received ACE inhibitors of whom, only 7 (9%)
patients received the target dose recommended by the
clinical practice guidelines. There was no documentation
in the records regarding patient counselling about medi-
cation, diet, weight, exercise or smoking. CONCLU-
SION: ACE inhibitors were underused in elderly patients
with heart failure; also achieving the target dose was
poor. This data demonstrated a very low rate of use of
echocardiography in elderly patients with heart failure.
Counseling appeared to be a neglectedaspect of patient
care.
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OBJECTIVES: Prophylactic anticoagulants, such as low
molecular weight heparin, to prevent thrombosis in hos-
pitalized medical patients has been recommended in clini-
cal guidelines, however the impact on quality adjusted
life years (QALYs) is unclear. This pilot study evaluated
enoxaparin for this indication among elderly (age 59)
hospitalized medical patients. METHODS: Patients were
randomized to receive subcutaneous injections of enox-
aparin 30 mg or placebo daily. Patients who had medical
indications for anticoagulation (e.g., myocardial infarc-
tion, history of thrombosis) were excluded. QALYs were
measured for the period of 30 to 90 days post random-
ization, using the Health Utilities Index(HUI). At 30 and
90 days, 51 and 40 patients in the active group com-
pleted the HUI versus 49 and 36 patients in the placebo
group, respectively. Surveys were received at both time
points among 40 enoxaparin and 21 placebo patients.
QALYs and changes in domain scores were analyzed
over the time between the two surveys. Data were ana-
lyzed using t-tests. RESULTS: Significantly more QALYs
were gained (p  .007)among enoxaparin treated pa-
tients. The mean QALY values were 0.005  0.015 vs
0.008  0.015. The change in the HUI, Mark III do-
main score for ambulation approached significance (p 
0.053. The mean values were 0.012  0.098 for enox-
aparin versus 0.027  0.056 for placebo. A significant
change in the HUI, Mark II domain score for mobility
was found (p  0.017, mean values 0.015  0.064 ver-
sus 0.022  0.050). CONCLUSION: Among medical
patients prophylactic treatment with enoxaparin was as-
sociated with increased QALYs.
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OBJECTIVES: With over one-third of the population
considered to be obese, obesity has reached epidemic pro-
portions in the US The direct costs associated with obe-
sity are currently estimated at about $238 billion. As the
underlying cause of various chronic diseases, obesity neg-
atively impacts quality of life due to impaired physical
and mental well being and reduced daily functions. The
objective of this study is to evaluate the relationship be-
tween obesity and health-related quality of life using the
Centers for Disease Control and Prevention’s (CDC) Be-
havioral Risk Factor Surveillance System (BRFSS) data.
METHODS: The BRFSS is an ongoing, state-based, ran-
dom digit dialed telephone survey of the civilian, non-
institutionalized population aged 3 18 years conducted by
CDC. Data from sixteen states that collected information
on health status (4 items), HRQoL (10 items), and demo-
graphic characteristics including weight and height from
50,454 participants in 1998 were utilized for the analy-
sis. Participants who had a Body Mass Index (BMI) 3 30
were defined as obese. Prevalence of obesity by demo-
graphics and disease presence was determined, as were
corresponding HRQoL scores. RESULTS: On the basis
of BMI, 31.9% of the respondents were identified as
obese. Obesity was higher in males as compared to fe-
males and higher among African-Americans and Hispan-
ics as compared to whites. Obesity increased with age but
decreased as income and education increased. Obese re-
spondents reported poorer health status. Impact of obe-
sity on HRQoL due to reduced physical and mental func-
tioning in the presence of no health problems, as well
as in presence of self-reported major health problems
such as arthritis, cardiovascular disease, diabetes, cancer,
depression, and pulmonary disease is discussed. CON-
CLUSIONS: Health related quality of life is significantly
affected due to obesity and should be an important con-
sideration in the treatment of obesity. It also has impor-
tant implications in case of illnesses that have obesity as
an underlying cause.
PCV15
ECONOMIC EVALUATION OF OUTPATIENT 
ANTICOAGULANT/ANTIPLATELET THERAPY 
FOLLOWING CORONARY STENTING IN A 
MANAGED CARE POPULATION
Liao E, Fronk M, Newell J, Huse D
PharMetrics, Inc, Watertown, MA, USA
OBJECTIVE: To determine the impact of outpatient an-
ticoagulant/antiplatelet therapy on treatment charges in
